53 results about "Immunologic Procedures" patented technology

The invention provides a triple live vaccine for a swine transmissible gastroenteritis virus, a swine epidemic diarrhea virus and a swine rotavirus and a preparation method thereof. The content of the three viruses is not less than 107.5 TCID50 (Tissue Culture Infectious Dose 50)/mL, and the volume ratio is 1:1:1. The triple live vaccine provided by the invention solves the problem that a multiple vaccine for effectively preventing and treating such three diseases as swine transmissible gastroenteritis, swine epidemic diarrhea and the swine rotavirus is not available on the current market, and especially realizes the prevention and control on the swine rotavirus. Compared with the existing method of inoculating with three simplex vaccines to prevent such three transmissible diseases, the triple live vaccine provided by the invention is economical to use, simplifies the immunization procedure and lowers the epidemic prevention cost, thereby providing a new simple and convenient immunization way for farms in China.

The invention provides a triple inactivated vaccine for porcine epidemic diarrhea (PED), porcine transmissible gastroenteritis (TGE) and porcine delta coronavirus (PDCoV) and a preparation method of the triple inactivated vaccine, before inactivation, the contents of the three viruses are greater than or equal to 10<7.0>TCID50/mL, and after inactivation, the volume ratio of the antigens is 1 to 1to 1. With the triple inactivated vaccine disclosed by the invention, the problem that an effective multivalent vaccine for preventing and treating three diseases including porcine epidemic diarrhea (PED), porcine transmissible gastroenteritis (TGE) and porcine delta coronavirus (PDCoV) is not available on the market is solved, especially, the problem that the vaccine for the porcine delta coronavirus (PDCoV) epidemic in recent years is not available is solved. The triple inactivated vaccine provided by the invention is economical and practical, the immunizing procedure is simplified, the epidemic prevention cost can be effectively reduced, and a novel method for simultaneously preventing the occurrence of the three diseases is provided for domestic breeding enterprises.

The present invention provides a trivalent inactivated vaccine of porcine reproductive and respiratory syndrome virus, porcine circovirus type 2, and porcine pseudorabies virus. Before inactivation, the contents of the three viruses are respectively greater than 10<8.5>TCID[50]/ml 10<6.0>TCID[50] /ml and 10<8.0>TCID[50]/ml; And after the inactivation, the volume ratio of the three antigens is 1:1:1. According to the present invention, via a large number of detailed tests, the contents and ratio of the three viral antigens are selected; and immune effects are measured in a large number of experimental animals and swine themselves, to ensure that the phenomenon of immune interference does not occur among the various immune components in the multivalent vaccine. Compared with the existing three individual vaccines of the same three virus, wherein three injections are need to prevent the three diseases caused by the three virus by using the three individual vaccines, the trivalent inactivated vaccine of the present invention is economical and practical, and simplifies the immunization procedure, and reduces the cost of epidemic prevention. The present invention realizes preparation and application of multivalent inactivated vaccine of porcine reproductive and respiratory syndrome virus, porcine circovirus type 2, and porcine pseudorabies virus, which has not been achieved for all the time in the field.

The invention relates to a detection card for rapidly detecting canine distemper virus antigens and a preparation method of the detection card. The method includes the following specific steps of: (1)the isolation, culture and purification of canine distemper viruses; (2) the preparation of paired monoclonal antibodies against the canine distemper viruses, wherein the preparation involves animmunization procedures, cell fusion, hybridoma screening and cloning, antibody preparation and purification; and (3) the preparation method of the colloidal gold detection card for rapidly detecting the canine distemper viruses, wherein the preparation method involves sample pad treatment, film spraying, and C, T line determination, to-be-tested sample processing and test card performance measurement.With the preparation method of the detection card of the invention adopted, canine distemper viruses in China can be quickly, sensitively and accurately detected. According to the prior art, paired monoclonal antibodies for developing colloidal gold detection cards for detecting canine distemper viruses in China are made of imported raw materials; the imported raw materials of the monoclonal antibodies are prepared from current viruses isolated by a certain country. With the preparation method of the invention adopted, the conditions in the prior art can be avoided, and a phenomenon that missed detection caused by virus variation due to long distances between areas during a detection process can be avoided.

The invention discloses a preparation method and application of a micro-capsule coated egg yolk antibody IgY resistant to main pathogenic bacteria of dairy cow mastitis. A compound mycoprotein antigen is prepared by selecting streptococcus agalactiae, streptococcus dysgalactiae, staphylococcus aureus and escherichia coli and is mixed with an equal quantity of freund's adjuvant to prepare a multivalence antigen immune complex, laying hens are immune by adopting repeatedly alternative immune procedures and a muscular and subcutaneous multipoint injection means, a specific yolk immunoglobulin IgY resistant to the main pathogenic bacteria of dairy cow mastitis, namely DP-BM-IgY, is separated and purified from collected egg yolk, then homogeneous emulsification is conducted on the specific yolk immunoglobulin and a sodium alginate water solution and an emulsifying agent soya bean salad oil containing span-80, the emulsified solution is dropwise added into an encystation solution prepared from CaCl2 and chitosan for coating and curing, and the coated micro-capsules can effectively protect the activity of the DP-BM-IgY and have enteric solubility. The preparation method utilizes a micro-capsule technology and selects the chitosan and sodium alginate as coating materials (natural polysaccharides), and the egg yolk antibody is internally taken and free of any toxic or side effect.

The invention relates to an antibody joint detection kit containing porcine pseudorabies virus gD and gE protein antibodies. The joint detection kit comprises one or more porcine pseudorabies virus gD and gE protein antibody detection chips and an enzyme-labeled reagent, the detection chips are coated with porcine pseudorabies virus gD protein, gE protein, a quality control product and a blank control point, the enzyme-labeled reagent is a solution containing an enzyme-labeled porcine pseudorabies virus gD and gE protein monoclonal antibody, the quality control product is a goat anti-mouse polyclonal antibody, and the coating amount is 1-4 ng/dot. According to the kit prepared by the invention, the quality control product is arranged on the reaction carrier, negative control does not need to be arranged in the kit, the detection is rapid, the operation is simple and convenient, the integration is high, one-button intelligent data processing is realized, the kit can be used for detecting the infection state of the porcine pseudorabies virus in a swinery, evaluating the immune effect of the porcine pseudorabies virus vaccine in the swinery and identifying the infection condition of the newly introduced porcine pseudorabies virus, and is convenient for formulating an immune program and carrying out early purification.

The invention belongs to the technical field of animal genetic engineering, and particularly relates to a preparation method of a genetic engineering vaccine for preventing staphylococcus caprae mastitis application. The preparation method comprises the following steps: 1) amplifying target genes ClfA, ClfA and Sbi; 2) building a Pci-Hla/ClfA-A/Sbi-I-II recombinant eukaryotic expression vector; and 3) establishing an immune procedure, and evaluating the immune result. According to the preparation method provided by the invention, the genetic engineering vaccine is on the basis of rapidly developed molecular biological technique, hereditary and immunology, and comprises a genetic subunit vaccine, a genetic mutation vaccine and a nucleic acid vaccine, wherein the nucleic acid vaccine is a DNA (Deoxyribose Nucleic Acid) vaccine, is an eukaryotic expression vector for to recombining and building one or more antigen-encoding genes, and can be directly injected into an organism to activate an immune system, so as to achieve the purpose of preventing and treating disease.

The embodiment of the invention discloses a preparation method of a monoclonal antibody for replacing an anti-mouse rabbit secondary antibody. The method comprises the steps of using purified rabbit serum as a holoantigen, and carrying out immunoreaction and cell fusion screening to obtain hybridoma cells. The embodiment of the invention provides the preparation method of a mouse non-specific monoclonal antibody, which uses the rabbit serum holoantigen as an immunogen, and obtains the anti-mouse rabbit secondary antibody used for replacing the prior art through immunogen purification, immune procedure, cell fusion, hybridoma screening and cloning, and antibody preparation and purification. The monoclonal antibody prepared by the embodiment of the invention is simple in preparation method,can be produced in batches, is good in stability, can be applied to immunochromatographic detection, is high in titer and strong in reaction, and is suitable for immunochromatographic reactions in various modes.

The invention relates to a vaccine composition for resisting pig mycoplasma pneumonia and infectious pleuropneumonia and a preparation method. The vaccine composition comprises pig mycoplasma hyopneumoniae antigens and pig actinobacillus pleuropneumoniae antigens, is simple in immunization procedure, not only is capable of generating antibodies, but also has the functions of toxicity attack protection and effectively controlling pig mycoplasma pneumonia and infectious pleuropneumonia. The vaccine composition has the immunization effect same to an independently injected vaccine, is small in side reaction, long in immunization period, less in consumed time, less in consumed labor, small in encroaching on a pig. The vaccine composition is simple in production technology, low in immunization cost and strong in practicality.

The invention provides a vaccine composition. The vaccine composition comprises SIV antigens in immune amount, Mhp antigens in immune amount, APP antigens in immune amount and a carrier acceptable on the veterinary medicine. The vaccine composition is simple in immune procedure; and single infecting or mixed infecting of SIV, Mhp and APP can be effectively prevented and treated. When mixed infecting occurs, the immune effect of the vaccine composition is obviously better than the immune effect of respectively-injected single vaccines. The vaccine composition is small in composition side reaction, long in immunity period, short in spent time, less in wasted labor, simple in production process, low in immune cost and high in practicability.

The invention discloses a method for preparing TW1 type avian infectious bronchitis virus positive serum from SPF chickens. An IBV virus seed of a specific genotype (TW1 type) is used. The method comprises the steps: the IBV CK/CH/XNGD/140 strain virus seed and an oil emulsion inactivated vaccine thereof are used for conducting basic immunization and enhanced immunization on SPF chickens which are50 days old, blood sampling is conducted, and serum is separated; and the TW1 type IBV positive serum with good specificity and high titer is obtained by carrying out sterile and exogenous virus detection, neutralization titer determination and specificity detection on the serum. The preparation method of the TW1 type IBV positive serum fills the blank that the TW1 type IBV virus seed has no standard positive serum. The SPF chickens are selected as test animals for preparing the serum, the immune procedure in the serum preparation process is optimized, and the serum antibody neutralization titer is improved. The production cost is reduced, and batch preparation of the positive serum is facilitated.

The invention discloses a porcine circovirus, porcine pseudorabies virus and mycoplasma triple inactivated vaccine which comprises an antigen and a vaccine adjuvant, the antigen is composed of a porcine circovirus type 2 antigen, a porcine pseudorabies virus antigen and a mycoplasma antigen, the porcine circovirus type 2 antigen is a purified, concentrated and inactivated porcine circovirus type 2 protein antigen solution, and the content of Cap protein is more than or equal to 160 [mu]g/ml; the porcine pseudorabies virus antigen is a purified, concentrated and inactivated porcine pseudorabies virus protein antigen solution, and the content of the Cap protein is more than or equal to 160 [mu]g/ml; the mycoplasma antigen is an inactivated mycoplasma protein antigen solution, and the content of the Cap protein is more than or equal to 160 [mu]g/ml; and the vaccine adjuvant is composed of a water-based high-molecular polymer adjuvant and a composite polysaccharide immunopotentiator. Foreign protein is removed through clarification filtration and ultrafiltration concentration, and the side reaction probability of the vaccine is greatly reduced; and three-proofing can be achieved through one needle, so that the number of immunization times and stress are reduced. The method is economical and practical, the immunization procedure is simplified, and the epidemic prevention cost is reduced.

The present invention relates to the composition and method of preparing an immunogen designated as I-spga consisting of a complex antigen prepared from 18 to 26 species of pathogenic microorganisms isolated from patients, inactivated with binary ethyleneamine (BEI) and formalin, diluted in a SPGA immunopotentiator mixed with QS-21 adjuvant. By inoculating the hens with the I-spga immunogen, hyperimmune eggs (Immunospga) are obtained which contain immunologically active proteins specific to the 18-26 antigens used for immunization. The immune response of the hens is specific to the used antigens by amplification of the antigenic signal by the SPGA immunopotentiator and due to a special immunization program that allows the immune system to act complex and intense: The I-spga complex antigen contains 18-26 microorganisms isolated from patients, bacterial bodies, components from bodies obtained by ultrasonography, cilia, exotoxins, endotoxins, spores, viruses, fungi or yeasts. This pathogenic material is inactivated with BEI and formalin. The I-spga antigen is of three types. The standard I-spga antigen is composed of 18 to 24 antibiotic-resistant bacterial species isolated from patients in Romania. The specific I-spga complex antigen is composed of the I-spga complex antigen containing a mixture of 7-9 strains from a single species of bacteria, fungi or yeasts isolated from patients in Romania mixed with SPGA and QS-21, used for inoculation of hens previously immunized with standard I-spga antigen. The personalized I-spga antigen is composed of patient-derived pathological material containing cellular debris and pathogenic germs inactivated with BEI and formalin and mixed with SPGA and QS-21 and is used to immunize hens previously immunized with the standard I-spga antigen. This now patented technology encompasses a new generation of biological products in which the immune response of the hens to different groups of parenterally inoculated antigens at different time intervals is overlapping. Chicken response is uniform and additional administration of immunogens and SPGA as an immunopotentiator amplifies the antigenic signal and immune response. The I-spga immunogen as well as the immune response contain two markers, G and A, which identify the I-spga antigen used for immunization against the antigens used to produce the Imunoinstant group bio-preparations or similar products. The I-spga immunogen is used to immunize the hens for obtaining immunologically active proteins that can be used to treat immune deficiencies, psoriasis, epidermolysis bullosa, other dermatitises, nosocomial infections, antibiotic-resistant infections in the urinary system of children and grownups.

The invention discloses a monoclonal antibody for detecting a new coronavirus. The formula of the monoclonal antibody for detecting the new coronavirus comprises the following components by weight: 1-3mg of antibody purified by protein G for ascetic fluid preparation, 0.5-1.5 mg of an antibody purified by antigen for ascetic fluid preparation, 1-3mg of an antibody purified by ammonium sulfate precipitation for ascetic fluid preparation, 1-3mg of an antibody purified by protein G for cell supernatant enlarge cultivation, 0.5-1.5 mg of an antibody purified by antigen for cell supernatant enlarge cultivation; the monoclonal antibody for detecting the new coronavirus comprises the following steps of S1, mouse ordering, S2, mouse immunization procedure, S3, fusion, S4, fusion detection and S5, monoclone; the monoclonal antibody for detecting the new coronavirus can effectively detect the new coronavirus, solves the problem of easy missed diagnosis in nucleic acid detection, increases IgM and IgG antibody detection when the nucleic acid detection is negative, can be used as a supplementary means for nucleic acid diagnosis, and greatly improves the accuracy of the new coronavirus detection.

The invention relates to a novel nucleic acid adjuvant system of a subunit vaccine and application of the novel nucleic acid adjuvant system, and belongs to the technical field of vaccine adjuvants. The novel nucleic acid adjuvant system of the subunit vaccine comprises a nucleic acid adjuvant, the nucleic acid adjuvant contains GC (Gas Chromatography) single-stranded oligodeoxynucleotide fragments (CpG ODN), and the GC single-stranded oligodeoxynucleotide fragments are 2395 and BW006. The novel nucleic acid adjuvant CpG ODN system and a suitable immune program can stimulate a mouse body to obtain relatively high humoral immunity and cellular immunity levels, and the immunity is biased to TH1 type, namely biased to cellular immune response type. Therefore, the potential risk of antibody-dependent infection enhancement of partially inactivated vaccines and subunit vaccines and the risk of severe lung immune pathology characterized by eosinophilic granulocyte infiltration are avoided, and vaccines partially dependent on cellular immune response level can obtain better protection effect.